These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 30153105)

  • 1. Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39.
    Derosa G; Cicero AFG; Carbone A; Querci F; Fogari E; D'Angelo A; Maffioli P
    J Am Soc Hypertens; 2015 Oct; 9(10):821. PubMed ID: 30153105
    [No Abstract]   [Full Text] [Related]  

  • 2. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.
    Derosa G; Cicero AF; Carbone A; Querci F; Fogari E; D'Angelo A; Maffioli P
    J Am Soc Hypertens; 2013; 7(1):32-9. PubMed ID: 23321403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies.
    Derosa G; Cicero AF; Carbone A; Querci F; Fogari E; D'Angelo A; Maffioli P
    J Clin Pharm Ther; 2013 Feb; 38(1):48-55. PubMed ID: 23216584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33].
    Derosa G; Cicero AFG; Carbone A; Querci F; Fogari E; D'Angelo A; Maffioli P
    Eur J Pharm Sci; 2018 Oct; 123():584. PubMed ID: 30190057
    [No Abstract]   [Full Text] [Related]  

  • 5. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients.
    Derosa G; Cicero AF; Carbone A; Querci F; Fogari E; D'Angelo A; Maffioli P
    Clin Exp Hypertens; 2013; 35(5):301-7. PubMed ID: 22954201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
    Erdine S
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):31-44. PubMed ID: 22222315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects.
    Bolbrinker J; Huber M; Scholze J; Kreutz R
    Fundam Clin Pharmacol; 2009 Dec; 23(6):767-74. PubMed ID: 19659504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428.
    Derosa G; Bonaventura A; Romano D; Bianchi L; Fogari E; D'Angelo A; Maffioli P
    J Am Soc Hypertens; 2015 Oct; 9(10):822. PubMed ID: 30153106
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone.
    Bilo G; Koch W; Hoshide S; Parati G
    Hypertens Res; 2014 Sep; 37(9):836-44. PubMed ID: 24942766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retraction: 'Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies' by G. Derosa, A. F. G. Cicero, A. Carbone, F. Querci, E. Fogari, A. D'Angelo and P. Maffioli.
    J Clin Pharm Ther; 2016 Apr; 41(2):237. PubMed ID: 27059120
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
    Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
    Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.
    Rosenson RS
    Cardiovasc Drugs Ther; 2009 Aug; 23(4):289-94. PubMed ID: 19641984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
    Vivencio B
    Curr Med Res Opin; 2009 Sep; 25(9):2267-8; author reply 2268-9. PubMed ID: 19630488
    [No Abstract]   [Full Text] [Related]  

  • 14. Retraction notice to "Urinary sodium or potassium excretion and blood pressure in adults of Shandong province, China: preliminary results of the SMASH project": [J Am Soc Hypertens 9 (2015) 754-762].
    J Am Soc Hypertens; 2016 May; 10(5):472. PubMed ID: 27155247
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.
    Axthelm C; Sieder C; Meister F; Kaiser E
    Curr Med Res Opin; 2012 Jan; 28(1):69-78. PubMed ID: 22117838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.
    Fogari R; Zoppi A; Mugellini A; Preti P; Perrone T; Maffioli P; Derosa G
    Expert Opin Pharmacother; 2012 Apr; 13(5):629-36. PubMed ID: 22372508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.
    Rohatagi S; Lee J; Shenouda M; Haworth S; Bathala MS; Allison M; Rubets I; Heyrman R; Noveck R; Salazar DE
    J Clin Pharmacol; 2008 Nov; 48(11):1309-22. PubMed ID: 18974285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
    Naya M; Tsukamoto T; Morita K; Katoh C; Furumoto T; Fujii S; Tamaki N; Tsutsui H
    J Am Coll Cardiol; 2007 Sep; 50(12):1144-9. PubMed ID: 17868805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects.
    Lee SY; Kim JR; Jung JA; Huh W; Bahng MY; Ko JW
    Drug Des Devel Ther; 2015; 9():2811-7. PubMed ID: 26082611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients.
    Schmieder RE; Böhm M
    J Hum Hypertens; 2011 Jun; 25(6):354-63. PubMed ID: 20686499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.